

Innovative, Intuitive, Flexible.

Luminex Flow Cytometry Solutions
with **Guava**[®] and **Amnis**[®] Systems

[Learn More >](#)



Luminex[®]
complexity simplified.

OMIP-020: Phenotypic Characterization of Human $\gamma\delta$ T-cells by Multicolor Flow Cytometry

Kilian Wistuba-Hamprecht,* Graham Pawelec, Evelyn Derhovanessian

Department of Internal Medicine II,
Centre for Medical Research, University
of Tübingen, Tübingen, Germany

Received 12 July 2013; Revised 18
February 2014; Accepted 26 March 2014

Grant sponsor: German Federal Ministry
of Education and Research (BMBF);
Grant number: 16SV5536K (BASE-II)

Grant sponsor: European Commission;
Grant number: FP7 259679 (IDEAL)

Additional Supporting Information may be
found in the online version of this article.

*Correspondence to: Kilian Wistuba-
Hamprecht, Department of Internal
Medicine II, Centre for Medical
Research, University of Tübingen,
Tübingen, Germany.
E-mail: kilian.wistuba-hamprecht@uni-
tuebingen.de

Published online 29 April 2014 in Wiley
Online Library (wileyonlinelibrary.com)

DOI: 10.1002/cyto.a.22470

© 2014 International Society for
Advancement of Cytometry

Key terms

$\gamma\delta$ T-cells; differentiation phenotype; human ageing; flow cytometry

PURPOSE AND APPROPRIATE SAMPLE TYPES

THIS panel was composed and optimized to investigate the differentiation stages of human $\gamma\delta$ T-cells in cryopreserved peripheral blood mononuclear cells (PBMC) from healthy individuals (Tables 1 and 2). As the majority of pan- $\gamma\delta$ T-cell antibodies available commercially proved to be inappropriate for detecting all $\gamma\delta$ T-cell populations in combination with other markers, this panel provides an essential tool for the analysis of different subsets of human $\gamma\delta$ T-cells by flow cytometry. The panel works very well with cryopreserved PBMC. Other tissues have not been tested.

BACKGROUND

Based on our long-standing experience of studying human $\alpha\beta$ T-cells [e.g., (1–3)], and an extensive survey of the published literature, we aimed to set up an antibody panel for the analysis of the differentiation status of circulating human $\gamma\delta$ T-cells. During the initial phase of panel development, we became aware that the majority of commercially available anti- $\gamma\delta$ TCR antibodies do not detect all $\gamma\delta$ T-cell subsets when used in combination with other markers in a multicolor flow cytometry panel. The following pan- $\gamma\delta$ T-cell antibodies were tested: an APC-conjugated antibody from clone B1, a PE-conjugated antibody from clone B1.1, and unconjugated, PE-Cy7- and FITC-conjugated antibodies from clone 11F2. Of these, the only pan- $\gamma\delta$ antibody we found able to stain all $V\delta 1^+$ T-cells (as identified by antibodies from clones TS8.2 & R9.12) and all $V\delta 2^+$ T-cells (as identified by antibodies from clones B6 & Immu 389), in a multicolor panel, was the unconjugated form of the clone 11F2 antibody. Having found a suitable marker for identification of all $\gamma\delta$ T-cells, other markers were added to the panel.

The panel as finally developed includes a live/dead marker^{EMA}, CD3^{Alexa 700}, CD4^{PerCP}, CD8^{APC-H7}, and the aforementioned pan- $\gamma\delta$ TCR^{indirect PO}, as a basis to identify $\gamma\delta$ T-cells. This combination allows the analysis of all $\gamma\delta$ T-cells and to distinguish the CD4⁻CD8⁻ cells from those expressing CD8 (4,5) (gating strategy provided in Supporting Information). Furthermore, $V\delta 1$ TCR^{FITC} and $V\delta 2$ TCR^{PerCP} markers were used to discriminate the two main $\gamma\delta$ T-cell populations in peripheral blood, also allowing the analysis of the remaining small pool of $V\delta 1^-V\delta 2^-$ circulating $\gamma\delta$ T-cells. EMA can be replaced by red dead stain without altering the performance of the panel (Supporting Information Fig. 8). It also works well after fixation

Table 1. Summary for application of OMIP-020

PURPOSE	$\gamma\delta$ T-CELL DIFFERENTIATION PHENOTYPE
Species	Human
Cell types	PBMC
Cross references	n.a.

and permeabilization (Supporting Information Fig. 5). CD27^{APC} and CD28^{PE} in combination with CD45RA^{Pacific Blue} was informative for the differentiation phenotype of the $\gamma\delta$ T-cell subsets as previously reported in several studies (5–14). Finally, we have included CD16^{BV711} in this panel, as it reportedly distinguishes between $\gamma\delta$ T-cell subsets with different activation pathways and functional properties (15–17) (Fig. 1).

In the process of setting up the panel, fluorescence minus one (FMO)-controls were measured for each marker to identify the best antibody and fluorophore combinations in the context of the whole panel. This panel has been used successfully for analyzing more than 250 healthy individuals (and

Table 2. Reagents used for OMIP-020

SPECIFICITY	FLUOROPHORE	CLONE
CD 3	Alexa 700	UCHT-1
CD 4	PE-Cy7	OKT4
CD 8	APC-H7	SK1
CD 16	BV 711	3G8
CD 27	APC	0323
CD 28	PE	CD28.2
CD 45 RA	Pacific Blue	H100
$\gamma\delta$ -TCR	Purified	11F2
V δ 1-TCR	FITC	TS8.2
V δ 2-TCR	PerCP	B6
F(ab') ₂ -Fragment goat anti-mouse	Pacific Orange	
Dead cells	EMA	

cancer patients). Data using a slimmed-down version of this panel (without CD16) were recently published (17).

SIMILARITY TO OTHER PUBLISHED OMIPS

Thus far, there are no other OMIPs published for $\gamma\delta$ T-cells.




Figure 1. Example of the gating strategy. (A) Gating of the sample starts with a time gate (not shown) to avoid cross-contamination followed by lymphocyte gating (1) and singlet-gating (2 and 3). To exclude dead cells, an EMA- “viable gate” (4) is set, followed by gating the CD3⁺ population (5) and the discrimination of the T cells into CD4 and CD8 subsets (6). CD4⁻CD8⁻ cells were then gated to enrich for $\gamma\delta$ T-cells (7) which were further discriminated into V δ 1⁺, V δ 2⁺, and V δ 1⁻V δ 2⁻ subpopulations (8). (B) Differentiation phenotyping of V δ 2 TCR⁺ and V δ 1 TCR⁺ (C) cells by their expression of CD27, CD28, CD45RA, and CD16. (The dot size in (B) and (C) is larger than in (A) to display the small populations better). [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]

ACKNOWLEDGMENTS

The authors thank Karin Hähnel and David Goldeck for technical support and Lilly Öttinger for the titration of some antibodies.

LITERATURE CITED

1. Derhovanessian E, Maier AB, Haehnel K, Zelba H, de Craen AJ, Roelofs H, Slagboom PE, Westendorp RG, Pawelec G. Lower proportion of naive peripheral CD8+ T cells and an unopposed pro-inflammatory response to human Cytomegalovirus proteins in vitro are associated with longer survival in very elderly people. *Age (Dordr)* 2013;35:1387–1399.
2. Derhovanessian E, Maier AB, Beck R, Jahn G, Haehnel K, Slagboom PE, de Craen AJ, Westendorp RG, Pawelec G. Hallmark features of immunosenescence are absent in familial longevity. *J Immunol* 2010;185:4618–4624.
3. Koch S, Larbi A, Derhovanessian E, Ozcelik D, Naumova E, Pawelec G. Multiparameter flow cytometric analysis of CD4 and CD8 T cell subsets in young and old people. *Immun Ageing* 2008;5:6.
4. Deusch K, Lueling F, Reich K, Classen M, Wagner H, Pfeffer K. A major fraction of human intraepithelial lymphocytes simultaneously expresses the gamma/delta T cell receptor, the CD8 accessory molecule and preferentially uses the V delta 1 gene segment. *Eur J Immunol* 1991;21:1053–1059.
5. Vantourout P, Hayday A. Six-of-the-best: Unique contributions of gammadelta T cells to immunology. *Nat Rev Immunol* 2013;13:88–100.
6. Morita CT, Jin C, Sarikonda G, Wang H. Nonpeptide antigens, presentation mechanisms, and immunological memory of human Vgamma2Vdelta2 T cells: Discriminating friend from foe through the recognition of prenyl pyrophosphate antigens. *Immunol Rev* 2007;215:59–76.
7. Dieli F, Poccia F, Lipp M, Sireci G, Caccamo N, Di Sano C, Salerno A. Differentiation of effector/memory Vdelta2 T cells and migratory routes in lymph nodes or inflammatory sites. *J Exp Med* 2003;198:391–407.
8. Pitard V, Roumanes D, Lafarge X, Couzi L, Garrigue I, Lafon ME, Merville P, Moreau JF, Dechanet-Merville J. Long-term expansion of effector/memory Vdelta2-gammadelta T cells is a specific blood signature of CMV infection. *Blood* 2008;112:1317–1324.
9. Dechanet J, Merville P, Lim A, Retiere C, Pitard V, Lafarge X, Michelson S, Meric C, Hallet MM, Kourilsky P, et al. Implication of gammadelta T cells in the human immune response to cytomegalovirus. *J Clin Invest* 1999;103:1437–1449.
10. De Rosa SC, Andrus JP, Perfetto SP, Mantovani JJ, Herzenberg LA, Herzenberg LA, Roederer M. Ontogeny of gamma delta T cells in humans. *J Immunol* 2004;172:1637–1645.
11. Couzi L, Pitard V, Netzer S, Garrigue I, Lafon ME, Moreau JF, Taupin JL, Merville P, Dechanet-Merville J. Common features of gammadelta T cells and CD8(+) alpha-beta T cells responding to human cytomegalovirus infection in kidney transplant recipients. *J Infect Dis* 2009;200:1415–1424.
12. Gioia C, Agrati C, Casetti R, Cairo C, Borsellino G, Battistini L, Mancino G, Goletti D, Colizzi V, Pucillo LP, et al. Lack of CD27-CD45RA-V gamma 9V delta 2+ T cell effectors in immunocompromised hosts and during active pulmonary tuberculosis. *J Immunol* 2002;168:1484–1509.
13. Qin G, Liu Y, Zheng J, Xiang Z, Ng IH, Malik Peiris JS, Lau YL, Tu W. Phenotypic and functional characterization of human gammadelta T-cell subsets in response to influenza A viruses. *J Infect Dis* 2012;205:1646–1653.
14. Roux A, Mourin G, Larsen M, Fastenackels S, Urrutia A, Gorochov G, Autran B, Donner C, Sidi D, Sibony-Prat J, et al. Differential impact of age and cytomegalovirus infection on the gammadelta T cell compartment. *J Immunol* 2013;191:1300–1306.
15. Wistuba-Hamprecht K, Frasca D, Blomberg B, Pawelec G, Derhovanessian E. Age-associated alterations in gammadelta T-cells are present predominantly in individuals infected with Cytomegalovirus. *Immun Ageing* 2013;10:26.
16. Couzi L, Pitard V, Sicard X, Garrigue I, Hawchar O, Merville P, Moreau JF, Dechanet-Merville J. Antibody-dependent anti-cytomegalovirus activity of human gammadelta T cells expressing CD16 (FcgammaRIIIa). *Blood* 2012;119:1418–1427.
17. Angelini DF, Borsellino G, Poupot M, Diamantini A, Poupot R, Bernardi G, Poccia F, Fournie JJ, Battistini L. FcgammaRIII discriminates between 2 subsets of Vgamma9Vdelta2 effector cells with different responses and activation pathways. *Blood* 2004;104:1801–1807.